Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Giovanni Satta

University College London Hospitals NHS Foundation Trust

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Microbiology

90%

Virology

60%

Antibiotic Therapy

50%

Tuberculosis Research

40%

Antibiotic Resistance

40%

Infectious Disease

30%

Bacterial Infection

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles17

Defining the pharmacokinetic/pharmacodynamic index of piperacillin/tazobactam within a hollow-fibre infection model to determine target attainment in intensive care patients

Article Link

Year:

2024

Improving the diagnosis of tuberculosis: old and new laboratory tools

Article Link

Year:

2024

Heteroresistance in tuberculosis: are we missing drug-resistant bacteria hiding in plain sight?

Article Link

Year:

2024

Recognition, diagnosis, and early management of suspected sepsis: summary of updated NICE guidance

Article Link

Year:

2024

Mastitis and Mammary Abscess Management Audit (MAMMA) in the UK and Ireland

Article Link

Year:

2024

End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries

Article Link

Year:

2023

The problem of Mycobacterium abscessus complex: multi-drug resistance, bacteriophage susceptibility and potential healthcare transmission

Article Link

Year:

2023

A comparison of phenotypic and WGS drug susceptibility testing in Mycobacterium tuberculosis isolates from the Republic of Korea

Article Link

Year:

2023

Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites

Article Link

Year:

2023

Coronavirus disease 2019 (COVID-19) impact on central-line-associated bloodstream infections (CLABSI): a systematic review

Article Link

Year:

2023

Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance

Article Link

Year:

2022

Whole genome sequencing and prediction of antimicrobial susceptibilities in non-tuberculous mycobacteria

Article Link

Year:

2022

Rare Mycobacteria and HIV in Children: Two Case Reports

Article Link

Year:

2022

Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19

Article Link

Year:

2022

Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections

Article Link

Year:

2022

Mortality and clinical cure rates for pneumonia: A systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments

Article Link

Year:

2022

Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment

Article Link

Year:

2021

Collaborators10

Benjamin H. Mullish

UNITED KINGDOM

Joseph Standing

University College London

UNITED KINGDOM

Benjamin M. C. Swift

Royal Veterinary College

UNITED KINGDOM

Mirae Park

Imperial College Healthcare NHS Trust

UNITED KINGDOM

Graham F. Hatfull

University of Pittsburgh

UNITED STATES

Professor Sir Alimuddin Zumla

University College London

UNITED KINGDOM

Timothy D McHugh

Professor

UCL

UNITED KINGDOM

Eleni Aklillu

Karolinska Institutet

SWEDEN

Pranabashis Haldar

Clinical Senior Lecturer and Honorary Consultant Respiratory Physician

University of Leicester

UNITED KINGDOM

Shanom Ali

Associate Professor - Microbiology

University College London

UNITED KINGDOM

How do I reach out?

Meet Kite AI